论文部分内容阅读
从“龙胆泻肝丸”到“鱼腥草注射液”,从“齐二药”到安徽华源,近年通过GMP认证的民族药企遭遇了接连出现的药品不良事件;并且从三九到华源再到东盛,无论是国企还是民营医药企业,在经过轰轰烈烈的并购整合后,也频频出现资本困局——中国民族医药企业会因这两重危困而搁浅吗?如何走出这样的困境已成为当下医药行业关注的热点话题,本刊为此结合近期发生的典型案例,就药企因药品不良反应和不良事件等药品安全质量问题、并购整合等资本运作问题进行了专题报道,以期对中国医药产业健康发展有所启发。
From “Long Dan Xie Gan Wan” to “Houttuynia Injection”, from “Qi Er Medicine” to Huayuan Anhui Province, in recent years, the GMP-certified national pharmaceutical companies have experienced successive adverse drug events; and from thirty-nine to Huayuan and then to Tung Shing, whether state-owned or private pharmaceutical companies, after a vigorous merger and acquisitions, there are frequent capital dilemma - the Chinese national pharmaceutical companies will be stranded because of these two risks? How to get out of this Dilemma has become the current hot topic of concern for the pharmaceutical industry, this journal combined with the recent case of a typical case, on pharmaceutical companies due to adverse drug reactions and adverse drug safety issues such as quality issues, mergers and acquisitions and other capital operation issues were reported, Inspired by the healthy development of China’s pharmaceutical industry.